A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
Kevin SheeJason D WellsMatthew UngRiley A HampschNicole A TraphagenWei YangStephanie C LiuMegan A ZeldenrustLiewei WangKrishna R KalariJia YuJudy C BougheyEugene DemidenkoArminja N KettenbachChao ChengMatthew P GoetzTodd W MillerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Our findings identify Hsp90i as a potential therapeutic strategy for a transcriptionally defined subgroup of ovarian and breast cancers. This study demonstrates that gene expression profiles may be useful to identify therapeutic vulnerabilities in tumor types with limited targetable genetic alterations, and to identify molecularly definable cancer subgroups that transcend lineage.